Abstract
Currently, there is no biomarker or effective treatment for Spinal and bulbar muscular atrophy (SBMA) patients. A recent clinical trial using Leuprorelin showed a modest effect on dysphagia, and an increased survival rate in SBMA. The aim of our study was to find an early marker of treatment efficiancy using Leuprorelin in 40 Korean SBMA patients. The Videofluoroscopic swallowing study (VFSS) and amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) were performed at baseline and after androgen suppression therapy for one year in these patients.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
